David F Friedlander1, Quoc-Dien Trinh2, Anna Krasnova3, Stuart R Lipsitz3, Maxine Sun3, Paul L Nguyen4, Adam S Kibel1, Toni K Choueiri4, Joel S Weissman3, Mani Menon5, Firas Abdollah5. 1. Brigham and Women's Hospital, Division of Urological Surgery, Harvard Medical School, Boston, MA, USA. 2. Brigham and Women's Hospital, Division of Urological Surgery, Harvard Medical School, Boston, MA, USA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: qtrinh@bwh.harvard.edu. 3. Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. 5. Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA.
Abstract
BACKGROUND: The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races. OBJECTIVE: To examine facility level variation in the use of definitive therapy among Black and White men for localized PCa. DESIGN, SETTING, AND PARTICIPANTS: Using data from the National Cancer Data Base, we identified 223 873 White and 59 262 Black men ≥40 yr of age receiving care within the USA with biopsy confirmed localized intermediate/high-risk PCa diagnosed between January 2004 and December 2013. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multilevel logistic regression was fitted to predict the odds of receiving definitive therapy for PCa. Sensitivity and subgroup analyses were performed to adjust for inherent patient and facility-level differences when appropriate. RESULTS AND LIMITATIONS: Eighty-three percent (n=185 647) of White men received definitive therapy compared with 74% (n=43 662) of Black men between 2004 and 2013. Overall rates of definitive therapy during that time increased for both White (81% vs 83%, p<0.001) and Black (73% vs 75%, p=0.001) men. However, 39% of treating facilities demonstrated significantly higher rates of definitive therapy in White men, compared with just 1% favoring Black men. Our study is limited by potential selection bias and effect modification. CONCLUSIONS: After adjusting for sociodemographic and clinical factors, we found that most facilities favored definitive therapy in Whites. Health care providers should be aware of these inherit biases when counseling patients on treatment options for localized PCa. Our study is limited by the retrospective nature of the cohort. PATIENT SUMMARY: We found significant differences in rates of radiation and surgical treatment for prostate cancer among White and Black men, with most facilities favoring Whites. Nonclinical factors such as treatment facility type and location influenced rates of therapy.
BACKGROUND: The gap in prostate cancer (PCa) survival between Blacks and Whites has widened over the past decade. Investigators hypothesize that this disparity may be partially attributable to differences in rates of definitive therapy between races. OBJECTIVE: To examine facility level variation in the use of definitive therapy among Black and White men for localized PCa. DESIGN, SETTING, AND PARTICIPANTS: Using data from the National Cancer Data Base, we identified 223 873 White and 59 262 Black men ≥40 yr of age receiving care within the USA with biopsy confirmed localized intermediate/high-risk PCa diagnosed between January 2004 and December 2013. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multilevel logistic regression was fitted to predict the odds of receiving definitive therapy for PCa. Sensitivity and subgroup analyses were performed to adjust for inherent patient and facility-level differences when appropriate. RESULTS AND LIMITATIONS: Eighty-three percent (n=185 647) of White men received definitive therapy compared with 74% (n=43 662) of Black men between 2004 and 2013. Overall rates of definitive therapy during that time increased for both White (81% vs 83%, p<0.001) and Black (73% vs 75%, p=0.001) men. However, 39% of treating facilities demonstrated significantly higher rates of definitive therapy in White men, compared with just 1% favoring Black men. Our study is limited by potential selection bias and effect modification. CONCLUSIONS: After adjusting for sociodemographic and clinical factors, we found that most facilities favored definitive therapy in Whites. Health care providers should be aware of these inherit biases when counseling patients on treatment options for localized PCa. Our study is limited by the retrospective nature of the cohort. PATIENT SUMMARY: We found significant differences in rates of radiation and surgical treatment for prostate cancer among White and Black men, with most facilities favoring Whites. Nonclinical factors such as treatment facility type and location influenced rates of therapy.
Authors: Walter Rayford; Alp Tuna Beksac; Jordan Alger; Mohammed Alshalalfa; Mohsen Ahmed; Irtaza Khan; Ugo G Falagario; Yang Liu; Elai Davicioni; Daniel E Spratt; Edward M Schaeffer; Felix Y Feng; Brandon Mahal; Paul L Nguyen; Robert B Den; Mark D Greenberger; Randy Bradley; Justin M Watson; Matthew Beamer; Lambros Stamatakis; Darrell J Carmen; Shivanshu Awasthi; Jonathan Hwang; Rachel Weil; Harri Merisaari; Nihal Mohamed; Leslie A Deane; Dimple Chakravarty; Kamlesh K Yadav; Kosj Yamoah; Sujit S Nair; Ashutosh K Tewari Journal: Commun Biol Date: 2021-06-03
Authors: Samuel L Washington; John Neuhaus; Maxwell V Meng; Sima P Porten Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-05-15 Impact factor: 4.254
Authors: Alexander P Cole; Peter Herzog; Hari S Iyer; Maya Marchese; Brandon A Mahal; Stuart R Lipsitz; Joshua Nyambose; Susan T Gershman; Mark Kennedy; Gail Merriam; Timothy R Rebbeck; Quoc-Dien Trinh Journal: Cancer Date: 2021-05-17 Impact factor: 6.921
Authors: Alexander P Cole; David-Dan Nguyen; Akezhan Meirkhanov; Mehra Golshan; Nelya Melnitchouk; Stuart R Lipsitz; Kerry L Kilbridge; Adam S Kibel; Zara Cooper; Joel Weissman; Quoc-Dien Trinh Journal: JAMA Netw Open Date: 2019-02-01
Authors: Bryce D Beutler; Mark B Ulanja; Rohee Krishan; Vijay Aluru; Munachismo L Ndukwu; Molly M Hagen; Zachary D Dupin; Charles E Willyard; Alastair E Moody; Killian Boampong-Konam; Steven C Zell Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302